indication for primary prophylaxis of FN by hGFs Table 2 describes the indications for primary prophylaxis of FN by hGFs and Table 3 gives examples of chemotherapy regimens with a risk of FN of 20%.
special situations for use of hGFs for standard therapy Table 4 describes special situations for the use of hGFs for standard therapy.
dose schedule, route of application of G-CSF and pegfilgrastim
Use 5 lg/kg/day of G-CSF subcutaneoulsy (s.c.) 24-72 h after the last day of chemotherapy until sufficient/stable post-nadir ANC recovery (achieving a target ANC of >10 · 10 9 /l is not necessary). Pegfilgrastim, injected s.c. as a single dose of either 100 lg/kg (individualized) or of a total dose of 6 mg (general approach), is considered equally effective [I, A].
note
Primary prophylaxis with G-CSF is not indicated during chemoradiotherapy to the chest due to the increased rate of bone marrow suppression associated with an increased risk of complications and death [I, A] .
There is also a risk of worsening thrombocytopenia when hGFs are given immediately before or simultaneously with chemotherapy.
There is a possible risk of subsequent acute myeloid leukaemia (AML) or myelodysplastic syndrome (MDS) in women receiving adjuvant chemotherapy for breast cancer and hGFs. However, this is confounded by the higher doses of chemotherapy received by patients receiving hGFs compared with those receiving standard dose reductions. Long-term follow-up of dose-dense adjuvant chemotherapy where total dose is the same has not demonstrated any difference in leukaemic risk. If an increased risk is confirmed in some settings, the absolute risk is low (1.8% compared with 0.7% within 48 months of breast cancer diagnosis) and, therefore, the benefits of hGFs still outweigh the risk.
use of G-CSF and pegfilgrastim in high-risk situations Therapy of acute leukaemias, autologous and allogeneic stem cell transplantations (TPLs) lead to higher risks of FN and potentially lethal complications.
Incidence of FN in high-risk situations: regular during autologous and allogeneic peripheral blood stem-cell (PBSC) TPLs and bone marrow TPL, during graft failure, in 35%-48% of AML cases at diagnosis and in 13%-30% during acute lymphoblastic leukaemia (ALL) induction chemotherapy.
Mortality: 0%-10% in autologous TPL, highly variable in allogeneic TPL, 80% during graft failure, 20%-26% during the first 2 months in AML and 2%-10% during induction of ALL.
indications for granulopoietic CSFs in high-risk situations benefit. In standard-risk patients outside trials are not recommended. 
G-CSF after allogeneic TPL

allogeneic PBSC
Donor convenience, recovery of ANC hastened, no increased rate of acute graft-versus-host disease. Faster ANC recovery after PBSC compared with marrow stem cells. The recommended dose of G-CSF is 10 lg/kg daily for 7-10 days before apheresis, with or without chemotherapy.
special comments on CSFs as a treatment for radiation injury
The use of CSFs as treatment for radiation injury is shown in Table 6 . 
